We have a huge opportunity to incentivize them.

Today's hearing provides us with an opportunity to examine an important aspect of the 21st Century Cures Initiative.

I urge my colleagues to take swift action and aggressive action because we do not have a moment to waste.

We must take a fresh look at the challenges facing innovative companies and make certain the right incentives are in place.

I hate to cut this off, but this has been the best interaction we have had with members and witnesses.

I and Ranking Member Pallone felt it important for the members of this subcommittee to hear the pros and cons of potential policies in this space.

Representative McKinley has authored H.R. 4673, a bill that would combine the various post-acute care payments into one reimbursement payment or bundle.

Representatives Mike Rogers and Doris Matsui introduced H.R. 2869, a proposal that would require Medicare to pay for cancer services at the same rate regardless of the site of service.

Today's hearing is designed to educate members on a topic that has come up repeatedly in recent years: site-neutral payments.

I urge the committee to address this crisis head-on, and encourage meaningful development in the antibiotic space.

Congress does not have all the answers, but we do have a role to play in ensuring our Nation's laws and regulations keep pace and complement the biomedical research and innovation that is happening at lightning speed.

I know people who have died of this rare disease. It is a terrible disease, and yet not once did anyone ever mention at that hearing the possibility of accelerated approval.

Through this effort, Congress hopes to clear a path to find more cures and treatments while also creating jobs and keeping America as the innovation center of the world.

Today's hearing relates to the 21st Century Cures Initiative announced by the Energy and Commerce Committee on April 30, 2014.

With Russian-backed militants creating chaos in Ukraine, neighboring Moldova has put their forces on high alert. Moldova and Ukraine share a similar problem of breakaway states within their borders. In fact, there is evidence that Russian…

The bottom line is that until we can attract more physicians to underserved communities and tighten the access gap, the best and most cost-efficient alternative is to improve telehealth networks.

One year ago today, April 30, 2014, the Energy and Commerce Committee embarked on an ambitious, bipartisan goal to develop legislation that would bring the medical innovation cycle of discovery, development, and delivery into the 21st…

The 2009 Tobacco Control Act was historic in saving legislation representing the first time the FDA was granted the authority to regulate tobacco products.

The Tobacco Control Act, TCA, was signed into the law on June 22, 2009.

The Tobacco Control Act (TCA) was signed into law on June 22, 2009.

As the oversight body, I believe we should be able to see how these funds are being used, the number of applications being reviewed or still pending, and get a clear picture of the division's work.

It now takes, on average, well over a billion dollars and 14 years from the time a drug is discovered to the time of approval.

This lack of predictability in the timing of DEA scheduling decisions leads to unnecessary uncertainty in the drug development process and needless delays in patients' access to new therapies.

H.R. 4299, the Improving Regulatory Transparency for New Medical Therapies Act, which Ranking Member Pallone and I introduced.

I would like to thank all of our witnesses for being here today, and I look forward to having a constructive discussion on these legislative proposals.